enGene (NASDAQ:ENGN) Rating Lowered to “Market Perform” at Citizens Jmp

enGene (NASDAQ:ENGN) was downgraded by equities researchers at Citizens Jmp from an “outperform” rating to a “market perform” rating in a research note issued to investors on Friday.

Other analysts have also recently issued research reports about the company. Citigroup cut enGene from a “market outperform” rating to a “market perform” rating in a research report on Friday. HC Wainwright cut their price objective on enGene from $25.00 to $6.00 and set a “buy” rating on the stock in a research note on Friday. Raymond James Financial lowered enGene from a “strong-buy” rating to an “outperform” rating and set a $4.00 target price for the company. in a report on Friday. Jefferies Financial Group began coverage on enGene in a research report on Friday, January 30th. They set a “buy” rating and a $28.00 target price for the company. Finally, Piper Sandler downgraded enGene from an “overweight” rating to a “neutral” rating and lowered their price target for the company from $7.00 to $4.00 in a report on Friday. Four equities research analysts have rated the stock with a Buy rating, nine have given a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, the company currently has an average rating of “Hold” and an average price target of $13.41.

enGene Stock Down 80.6%

enGene stock opened at $1.72 on Friday. The company has a market capitalization of $115.21 million, a P/E ratio of -0.76 and a beta of -0.02. The firm’s fifty day simple moving average is $7.60 and its 200-day simple moving average is $8.30. The company has a current ratio of 11.75, a quick ratio of 11.75 and a debt-to-equity ratio of 0.09. enGene has a 1-year low of $1.70 and a 1-year high of $12.25.

enGene (NASDAQ:ENGN) last issued its quarterly earnings data on Monday, March 9th. The company reported ($0.44) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.55) by $0.11. Sell-side analysts forecast that enGene will post -2.06 earnings per share for the current fiscal year.

Hedge Funds Weigh In On enGene

Institutional investors have recently made changes to their positions in the business. PFS Partners LLC lifted its position in shares of enGene by 22.2% during the 4th quarter. PFS Partners LLC now owns 11,000 shares of the company’s stock worth $99,000 after purchasing an additional 2,000 shares during the last quarter. Millennium Management LLC grew its holdings in enGene by 57.3% in the 3rd quarter. Millennium Management LLC now owns 20,502 shares of the company’s stock valued at $140,000 after buying an additional 7,472 shares during the last quarter. Raymond James Financial Inc. increased its position in enGene by 383.6% in the 3rd quarter. Raymond James Financial Inc. now owns 10,000 shares of the company’s stock worth $68,000 after buying an additional 7,932 shares during the period. Cresset Asset Management LLC bought a new position in enGene in the 2nd quarter worth approximately $36,000. Finally, Paloma Partners Management Co acquired a new position in shares of enGene during the second quarter worth approximately $38,000. 64.16% of the stock is currently owned by institutional investors.

enGene Company Profile

enGene Holdings Inc, through its subsidiary enGene, Inc, operates as a clinical-stage biotechnology company that develops genetic medicines through the delivery of therapeutics to mucosal tissues and other organs. Its lead product candidate is EG-70 (detalimogene voraplasmid), which is a non-viral immunotherapy to treat non-muscle invasive bladder cancer patients with carcinoma-in-situ (Cis), who are unresponsive to treatment with Bacillus Calmette-Guérin. The company was founded in 2023 and is based in Saint-Laurent, Canada.